Gain Therapeutics, Inc. (GANX)
NASDAQ:GANX
Want to see GANX full AI Analyst Report?
GANX Stock Chart & Stats
$2.13
-$0.01(-0.44%)
At close: 4:00 PM EST
$2.13
-$0.01(-0.44%)
Day’s Range― - ―
52-Week Range$1.41 - $4.34
Previous CloseN/A
Volume74.47K
Average Volume (3M)704.71K
Market Cap
$80.62M
Enterprise Value$54.24M
Total Cash (Recent Filing)$20.84M
Total Debt (Recent Filing)$732.07K
Price to Earnings (P/E)―
Beta1.86
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding42,241,947
10 Day Avg. Volume582,357
30 Day Avg. Volume704,713
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)5.72
Price to Sales (P/S)0.00
P/FCF Ratio-5.75
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-576.74
Enterprise Value/Ebitda-2.92
Forecast
1Y Price Target
$7.50Price Target Upside252.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Advancement Toward Phase 2Submission of an investigational new drug application to initiate a larger dose-finding Phase 2 trial positions the program to evaluate clinical benefit in a broader patient group pending regulatory clearance.
Safety And Brain PenetrationGT-02287 demonstrated favorable safety and central nervous system penetration in early studies, supporting tolerability and ability to reach target brain tissue.
Target Engagement Via BiomarkersConsistent reductions in a disease-linked lipid biomarker and related enzyme markers indicate GT-02287 engages its intended target, supporting a plausible biological effect.
Bears Say
Biomarker Predictive UncertaintyDoubts about whether changes in the key lipid biomarker will translate into meaningful clinical improvement create uncertainty that biomarker results may not predict patient outcomes.
Financing And Dilution RiskLimited cash reserves relative to ongoing development needs increase the likelihood of additional financing that could dilute existing shareholders and pressure the stock.
Small Trial Size And Inconclusive OutcomesA small, short Phase 1b study with modest patient numbers makes functional outcome measures inconclusive and requires larger, longer trials to confirm any disease-modifying effects.
Gain Therapeutics News
GANX FAQ
What was Gain Therapeutics, Inc.’s price range in the past 12 months?
Gain Therapeutics, Inc. lowest stock price was $1.41 and its highest was $4.34 in the past 12 months.
What is Gain Therapeutics, Inc.’s market cap?
Gain Therapeutics, Inc.’s market cap is $80.62M.
When is Gain Therapeutics, Inc.’s upcoming earnings report date?
Gain Therapeutics, Inc.’s upcoming earnings report date is May 19, 2026 which is in 18 days.
How were Gain Therapeutics, Inc.’s earnings last quarter?
Gain Therapeutics, Inc. released its earnings results on Mar 26, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.144 by $0.034.
Is Gain Therapeutics, Inc. overvalued?
According to Wall Street analysts Gain Therapeutics, Inc.’s price is currently Undervalued.
Does Gain Therapeutics, Inc. pay dividends?
Gain Therapeutics, Inc. does not currently pay dividends.
What is Gain Therapeutics, Inc.’s EPS estimate?
Gain Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gain Therapeutics, Inc. have?
Gain Therapeutics, Inc. has 42,241,947 shares outstanding.
What happened to Gain Therapeutics, Inc.’s price movement after its last earnings report?
Gain Therapeutics, Inc. reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.144. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Gain Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gain Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (252.11% Upside)
$7.50 (252.11% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 70%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.33%
12-Months-Change
Fundamentals
Return on Equity
-237.54%
Trailing 12-Months
Asset Growth
88.22%
Trailing 12-Months
Company Description
Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
GANX Stock 12 Month Forecast
Average Price Target
$7.50
▲(252.11% Upside)
Technical Analysis
Plus Therapeutics
―
ABVC BioPharma
―
PMV Pharmaceuticals
―
Prelude Therapeutics
―
Immix Biopharma
―
Ownership Overview
3.03%
Insiders
1.70% Mutual Funds
0.18% Other Institutional Investors
93.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---